uniQure N.V. announced the completion of enrollment for the first cohort of its Phase I/IIa trial for AMT-191, a gene therapy aimed at treating Fabry disease. The Independent Data Monitoring Committee ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results